genXone Valuation

Is GX1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GX1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GX1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GX1's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GX1?

Other financial metrics that can be useful for relative valuation.

GX1 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.1x
Enterprise Value/EBITDA-5.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does GX1's PS Ratio compare to its peers?

The above table shows the PS ratio for GX1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average23.5x
BER Bioerg Spólka Akcyjna
46.1xn/azł13.8m
SCS Stem Cells Spin
40.7xn/azł14.2m
GEN Genomed Spólka Akcyjna
1.7xn/azł37.0m
RDG Read-Gene
5.7xn/azł61.1m
GX1 genXone
10.3xn/azł20.8m

Price-To-Sales vs Peers: GX1 is good value based on its Price-To-Sales Ratio (10.3x) compared to the peer average (16x).


Price to Earnings Ratio vs Industry

How does GX1's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: GX1 is expensive based on its Price-To-Sales Ratio (10.3x) compared to the European Biotechs industry average (10x).


Price to Sales Ratio vs Fair Ratio

What is GX1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GX1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GX1's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.